BioInItaly Newsletter

La vetrina del biotech italiano all’estero


09 feb, 2016

Kedrion Biopharma strengthens its position on the US Market
Kedrion Biopharma will commercialize a 10% concentrated intravenous liquid immunoglobulin (IVIg) on the US market, indicated for the treatment of Primary Immunodeficiencies (PI), on an exclusive basis. The product will enable the company, based in Castelvecchio Pascoli (Lucca), Italy’s leader and the 5th most important manufacturer of plasma-derived products in the world, to strengthen its immunoglobulin portfolio in the US.
The result is a seven year agreement signed with the US company Biotest Pharmaceuticals Corporation, a subsidiary of Biotest AG, Dreieich, Germany.
The present agreement will enable Kedrion Biopharma to further increase the turnover generated by its operations in the US, which are currently the Lucca-based company’s main market (accounting, in 2014, for 160 Million Euros of company’s overall turnover of 466 Million Euros). In addition to which, this deal will have implications on Kedrion Biopharma’s activities in Italy too, as it has already been decided that, in the future, a phase of the manufacturing process (filling) will be carried out at the company’s facility in Bolognana, Lucca.
“Under this agreement – commented Paolo Marcucci, Kedrion Biopharma President and CEO – we will have the chance not only to grow further on what is considered  the most important market in the world; we will also be able to stand out as a market leader in plasma-derived therapies for the treatment of rare diseases. An area in which Kedrion Biopharma has been working hard since its foundation and with growing commitment, in partnership with patients’ associations, with the ultimate goal of broadening as much as possible the access to care for all those who need it”.

AbbVie invests in Italy: 60 million dollars in arrival to the manufacturing site
A 60 million dollar investment to establish, at Italy’s manufacturing site, a state-of-the-art manufacturing line aimed to perform assembly and packaging for global markets of leading drugs of the global biopharmaceutical company AbbVie. This new investment strengthens AbbVie Italia’s position in the Italian pharmaceutical industry sector: as confirmed by the 2014 data released recently by the Centro Studi Farmindustria , the company ranks second amongst global foreign companies for international sales and fourth in terms of the number of research and manufacturing personnel.
This will strengthen even more the export manufacturing capabilities of AbbVie Italy: currently, 90% of its chemical plant and 70% of the pharmaceutical plant’s output are already marketed internationally reaching more than 110 countries.
“AbbVie’s choice to invest in the Italian site – explained Azita Saleki-Gerhardt. AbbVie’s Operations President - is the result of the Campoverde di Aprilia (Latina) manufacturing site’s excellence and top-tier quality standards – results that were possible also thanks to the commitment and dedication of a qualified Team that builds upon it talents.”
“This new investment in Italy represents a further milestone for the company and a success for the country, to be consolidated by guaranteeing a stable law framework with clear and unchanging rules, and with a new governance that is more fair and innovation oriented – said Fabrizio Greco, Managing Director of AbbVie Italia.”

Zambon launches Xadago® (Safinamide) in Switzerland for patients with parkinson’s disease
Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and its partner Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announced the launch of Xadago® (safinamide) in Switzerland, the second market after Germany. Swissmedic approved Xadago® (safinamide) on Nov. 12 as add-on therapy to levodopa (L-dopa) alone or in combination with other therapies for patients with Parkinson’s disease (PD) in mid-to late-stage and motor fluctuations.
“We are pleased that, so soon after the approval by Swissmedic, patients with Parkinson’s disease in Switzerland now have access to Xadago®, an innovative, add-on treatment option that has shown meaningful improvements in ‘ON and OFF time’ without any increase in Parkinson’s disease symptoms such as dyskinesia,” said Maurizio Castorina, CEO of Zambon S.p.A. “Additionally, we are pleased with the positive reception of Xadago® in Germany and are finalizing preparations for a series of additional launches in EU countries during 2016.” “It is truly rewarding to see Xadago® available to patients in Germany and Switzerland, and we look forward to patients with Parkinson’s disease around the world having access to this important therapeutic option,” said Stefan Weber, CEO of Newron Pharmaceuticals

BioInItaly Investment Forum 2016, where biotech meets investors. 19-20 April in Milan
Assobiotec, the Italian Association for the Development of Biotechnology, together with Intesa Sanpaolo, is proud to present BioInItaly Investment Forum 2016 and Intesa Sanpaolo Start-Up Initiative from April 19 to April 20 in Milan, Italy. This event will bring together national and international financial and corporate investors and biotech companies from all fields of application.
BioInItaly Investment Forum & Intesa Sanpaolo Start-Up Initiative is a yearly investment forum open to established biotech and nanobiotech companies, start-ups and projects from Italy but also from other European countries seeking for financial resources. In a unique end-to-end program, the applicants will benefit from coaching, networking and direct contact with international investors through a series of focused events. The initiative is aimed to provide the applicants with the competences, connections and access to potential Investors they need to go to market and scale. The projects will be selected by a committee of experts in the biotech field. The meeting will take place in Milan, at the Palazzo Besana, Piazza Belgioioso 1, very close to Piazza Duomo (Subway Line 1 and 3, Stop: Duomo). Investors are welcome. To register: